X4 Pharmaceuticals, Inc.
XFORNASDAQHealthcare● Active
$3.88
+$0.17(+4.58%)
Market Cap$365960420
P/E Ratio—
52W High$4.83
52W Low$1.35
X4 Pharmaceuticals, Inc. (XFOR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · XFOR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $35.11M | $2.56M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $6.26M | $0.80M | $0.00M | $0.00M | $1.89M |
| Gross Profit | $28.86M | $1.76M | $0.00M | $0.00M | ($1.89M) |
| Gross Margin %(computed) | 82.18% | 68.83% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $72.22M | $81.64M | $72.02M | $61.06M | $48.76M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $115.74M | $38.16M | $107.52M | $87.57M | $73.46M |
| Operating Income | ($86.88M) | ($36.40M) | ($107.52M) | ($87.57M) | ($75.35M) |
| Operating Margin %(computed) | -247.44% | — | — | — | — |
| Interest Income | $4.58M | $5.77M | $4.58M | $0.22M | $0.01M |
| Interest Expense | $8.88M | $8.77M | $5.78M | $3.99M | $3.64M |
| Income Before Tax | ($79.16M) | ($37.14M) | ($101.09M) | ($93.84M) | ($88.68M) |
| Income Tax Expense | $0.04M | $0.31M | $0.08M | $0.03M | $0.02M |
| Net Income | ($79.20M) | ($37.45M) | ($101.17M) | ($93.87M) | ($88.70M) |
| Net Margin %(computed) | -225.55% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.87 | $-5.59 | $-17.07 | $-45.60 | $-119.58 |
| Wtd Avg Shares | 42.29M | 6.70M | 5.93M | 2.12M | 0.86M |
| EBITDA | ($85.61M) | ($27.58M) | ($94.89M) | ($89.33M) | ($73.46M) |
| EBITDA Margin %(computed) | -243.80% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more X4 Pharmaceuticals, Inc. data
About X4 Pharmaceuticals, Inc. (XFOR) Income Statement
X4 Pharmaceuticals, Inc. (XFOR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, XFOR reported revenue of $0.04B, gross profit of $0.03B (gross margin 82.18%), and net income of ($0.08B) — a net profit margin of -225.55%.
Frequently asked questions
XFOR · 4 questionsX4 Pharmaceuticals, Inc. (XFOR) reported revenue of $0.04B for 2025, up 1273.2% year-over-year.
XFOR revenueXFOR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09